Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India.

MLA

Chugh, Yashika, et al. “Real-World Cost-Effectiveness of Pan-Genotypic Sofosbuvir-Velpatasvir Combination versus Genotype Dependent Directly Acting Anti-Viral Drugs for Treatment of Hepatitis C Patients in the Universal Coverage Scheme of Punjab State in India.” PLoS ONE, vol. 14, no. 8, Aug. 2019, pp. 1–24. EBSCOhost, https://doi.org/10.1371/journal.pone.0221769.

APA

Chugh, Y., Dhiman, R. K., Premkumar, M., Prinja, S., Singh Grover, G., & Bahuguna, P. (2019). Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India. PLoS ONE, 14(8), 1–24. https://doi.org/10.1371/journal.pone.0221769

Chicago

Chugh, Yashika, Radha Krishan Dhiman, Madhumita Premkumar, Shankar Prinja, Gagandeep Singh Grover, and Pankaj Bahuguna. 2019. “Real-World Cost-Effectiveness of Pan-Genotypic Sofosbuvir-Velpatasvir Combination versus Genotype Dependent Directly Acting Anti-Viral Drugs for Treatment of Hepatitis C Patients in the Universal Coverage Scheme of Punjab State in India.” PLoS ONE 14 (8): 1–24. doi:10.1371/journal.pone.0221769.